Table 2 All-cause adverse events.

From: Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

 

ERd (n = 318)

Rd (n = 317)

Any grade

Grade 3–4

Events/100 PYa

Any grade

Grade 3–4

Events/100 PYb

Event

316 (99)

244 (77)

NR

314 (99)

217 (68)

NR

AEs in ≥30% of patients

 Diarrhea

160 (50)

24 (8)

NR

125 (39)

17 (5)

NR

 Fatigue

155 (49)

32 (10)

NR

131 (41)

27 (9)

NR

 Anemia

139 (44)

57 (18)

NR

120 (38)

53 (17)

NR

 Pyrexia

129 (41)

11 (3)

NR

81 (26)

11 (3)

NR

 Constipation

115 (36)

4 (1)

NR

89 (28)

1 (<1)

NR

 Neutropenia

114 (36)

86 (27)

NR

137 (43)

109 (34)

NR

 Cough

109 (34)

1 (<1)

NR

62 (20)

0

NR

 Back pain

108 (34)

19 (6)

NR

98 (31)

17 (5)

NR

 Muscle spasm

100 (31)

2 (1)

NR

85 (27)

3 (1)

NR

 Peripheral edema

95 (30)

4 (1)

NR

78 (25)

1 (<1)

NR

AEs/AE categories of special interest

 Infections

267 (84)

112 (35)

199

239 (75)

85 (27)

185

 Pneumonia

69 (22)

48 (15)

13

51 (16)

33 (10)

12

 Herpes zoster

23 (7)

6 (2)

3

7 (2)

2 (1)

1

 Sepsisc

13 (4)

11 (3)

NR

13 (4)

6 (2)

NR

 Renal and urinary disorders

87 (27)

17 (5)

17

60 (19)

15 (5)

17

 Cardiac disorders

75 (24)

18 (6)

17

59 (19)

24 (8)

18

 Lymphopenia

41 (13)

27 (8)

12

23 (7)

12 (4)

11

 SPMs

39 (12)

NR

5d

28 (9)

NR

4e

 Basal cell carcinoma

11 (3)

NR

1d

6 (2)

NR

1e

 Squamous cell carcinoma of the skin

10 (3)

NR

1d

6 (2)

NR

1e

Total serious AEs

238 (75)

169 (53)

NR

194 (61)

127 (40)

NR

  1. Data are n (%).
  2. AE adverse event, ERd elotuzumab plus lenalidomide and dexamethasone, NR not reported, PY patient-years, Rd lenalidomide and dexamethasone, SPM second primary malignancy.
  3. a746.70 PY.
  4. b543.77 PY.
  5. cIncludes urosepsis, bacterial, biliary, neutropenic, pneumococcal, pseudomonal, pulmonary, device-related, and staphylococcal sepsis.
  6. dAdjusted based on 1166.98 PY of follow-up.
  7. eAdjusted based on 1050.78 PY of follow-up.